Hundreds of Studies Show COVID-19 Jabs Cause Harm

By LifeSite News February 18, 2022

LifeSite News has posted an article linking to hundreds of studies showing that the COVID jabs indeed pose dangers. See some of the links to these studies below:

Cerebral venous thrombosis after COVID-19 vaccination in the UK: a multicentre cohort study:

Fatal cerebral hemorrhage after COVID-19 vaccine:

Myocarditis after mRNA vaccination against SARS-CoV-2, a case series:

Three cases of acute venous thromboembolism in women after vaccination against COVID-19:

Acute thrombosis of the coronary tree after vaccination against COVID-19:

US case reports of cerebral venous sinus thrombosis with thrombocytopenia after vaccination with Ad26.COV2.S (against covid-19), March 2 to April 21, 2020:

Portal vein thrombosis associated with ChAdOx1 nCov-19 vaccine:

Management of cerebral and splanchnic vein thrombosis associated with thrombocytopenia in subjects previously vaccinated with Vaxzevria (AstraZeneca): position statement of the Italian Society for the Study of Hemostasis and Thrombosis (SISET):

Vaccine-induced immune immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis after vaccination with COVID-19; a systematic review:

Thrombosis with thrombocytopenia syndrome associated with COVID-19 vaccines:

Covid-19 vaccine-induced thrombosis and thrombocytopenia: a commentary on an important and practical clinical dilemma:

Thrombosis with thrombocytopenia syndrome associated with COVID-19 viral vector vaccines:

COVID-19 vaccine-induced immune-immune thrombotic thrombocytopenia: an emerging cause of splanchnic vein thrombosis:

The roles of platelets in COVID-19-associated coagulopathy and vaccine-induced immune thrombotic immune thrombocytopenia (covid):

Roots of autoimmunity of thrombotic events after COVID-19 vaccination:

Cerebral venous sinus thrombosis after vaccination: the United Kingdom experience:

Thrombotic immune thrombocytopenia induced by SARS-CoV-2 vaccine:

Myocarditis after immunization with COVID-19 mRNA vaccines in members of the US military. This article reports that in “23 male patients, including 22 previously healthy military members, myocarditis was identified within 4 days after receipt of the vaccine”:

Thrombosis and thrombocytopenia after vaccination with ChAdOx1 nCoV-19:

Association of myocarditis with the BNT162b2 messenger RNA COVID-19 vaccine in a case series of children:

Thrombotic thrombocytopenia after vaccination with ChAdOx1 nCov-19:

Post-mortem findings in vaccine-induced thrombotic thrombocytopenia (covid-19):

Thrombocytopenia, including immune thrombocytopenia after receiving COVID-19 mRNA vaccines reported to the Vaccine Adverse Event Reporting System (VAERS):

Acute symptomatic myocarditis in seven adolescents after Pfizer-BioNTech COVID-19 vaccination:

Aphasia seven days after the second dose of an mRNA-based SARS-CoV-2 vaccine. Brain MRI revealed an intracerebral hemorrhage (ICBH) in the left temporal lobe in a 52-year-old man.

Comparison of vaccine-induced thrombotic episodes between ChAdOx1 nCoV-19 and Ad26.COV.2.S vaccines:

Hypothesis behind the very rare cases of thrombosis with thrombocytopenia syndrome after SARS-CoV-2 vaccination:

Blood clots and bleeding episodes after BNT162b2 and ChAdOx1 nCoV-19 vaccination: analysis of European data:

Cerebral venous thrombosis after BNT162b2 mRNA SARS-CoV-2 vaccine:

Primary adrenal insufficiency associated with thrombotic immune thrombocytopenia induced by the Oxford-AstraZeneca ChAdOx1 nCoV-19 vaccine (VITT):

Myocarditis and pericarditis after vaccination with COVID-19 mRNA: practical considerations for care providers:

“Portal vein thrombosis occurring after the first dose of SARS-CoV-2 mRNA vaccine tion with COVID-19: a case report:

Guillain-Barré syndrome after the first injection of ChAdOx1 nCoV-19 vaccine: first report:

SARS-CoV-2 vaccines are not safe for those with Guillain-Barre syndrome following vaccination:

Acute hyperactive encephalopathy following COVID-19 vaccination with dramatic response to methylprednisolone: a case report:

Facial nerve palsy following administration of COVID-19 mRNA vaccines: analysis of self-report database:

Neurological symptoms and neuroimaging alterations related to COVID-19 vaccine: cause or coincidence:

New-onset refractory status epilepticus after ChAdOx1 nCoV-19 vaccination:

Acute myelitis and ChAdOx1 nCoV-19 vaccine: coincidental or causal association:

Bell’s palsy and SARS-CoV-2 vaccines: an unfolding story:

Bell’s palsy after the second dose of the Pfizer COVID-19 vaccine in a patient with a history of recurrent Bell’s palsy:

Acute-onset central serous retinopathy after immunization with COVID-19 mRNA vaccine:.

Bell’s palsy after COVID-19 vaccination: case report:

An academic hospital experience assessing the risk of COVID-19 mRNA vaccine using patient’s allergy history:

COVID-19 vaccine-induced axillary and pectoral lymphadenopathy in PET:

ANCA-associated vasculitis after Pfizer-BioNTech COVID-19 vaccine:

Late cutaneous reactions after administration of COVID-19 mRNA vaccines:

COVID-19 vaccine-induced rhabdomyolysis: case report with review of the literature:

Clinical and pathologic correlates of skin reactions to COVID-19 vaccine, including V-REPP: a registry-based study:

Thrombosis with thrombocytopenia syndrome associated with COVID-19 vaccines:.

COVID-19 vaccine-associated anaphylaxis: a statement from the Anaphylaxis Committee of the World Allergy Organization:.

Cerebral venous sinus thrombosis negative for anti-PF4 antibody without thrombocytopenia after immunization with COVID-19 vaccine in an elderly, non-comorbid Indian male treated with conventional heparin-warfarin-based anticoagulation:.

Acute myocarditis after administration of BNT162b2 vaccine against COVID-19:.

Blood clots and bleeding after BNT162b2 and ChAdOx1 nCoV-19 vaccine: an analysis of European data:.

immune thrombocytopenia associated with Pfizer-BioNTech’s COVID-19 BNT162b2 mRNA vaccine:.

Bullous drug eruption after the second dose of COVID-19 mRNA-1273 (Moderna) vaccine: Case report:

COVID-19 RNA-based vaccines and the risk of prion disease: ease-1503.pdf

This study notes that 115 pregnant women lost their babies, out of 827 who participated in a study on the safety of covid-19 vaccines:

Process-related impurities in the ChAdOx1 nCov-19 vaccine:

COVID-19 mRNA vaccine causing CNS inflammation: a case series:

Allergic reactions, including anaphylaxis, after receiving the first dose of the Pfizer-BioNTech COVID-19 vaccine:

Allergic reactions to the first COVID-19 vaccine: a potential role of polyethylene glycol:

Pfizer Vaccine Raises Allergy Concerns:

Allergic reactions, including anaphylaxis, after receiving the first dose of Pfizer-BioNTech COVID-19 vaccine – United States, December 14-23, 2020:

Allergic reactions, including anaphylaxis, after receiving first dose of Modern COVID-19 vaccine – United States, December 21, 2020-January 10, 2021:

Reports of anaphylaxis after coronavirus disease vaccination 2019, South Korea, February 26-April 30, 2021:

Reports of anaphylaxis after receiving COVID-19 mRNA vaccines in the U.S.-Dec 14, 2020-Jan 18, 2021:

Immunization practices and risk of anaphylaxis: a current, comprehensive update of COVID-19 vaccination data:

Relationship between pre-existing allergies and anaphylactic reactions following administration of COVID-19 mRNA vaccine:

Anaphylaxis Associated with COVID-19 mRNA Vaccines: Approach to Allergy Research:

Severe Allergic Reactions after COVID-19 Vaccination with the Pfizer / BioNTech Vaccine in Great Britain and the USA: Position Statement of the German Allergy Societies: German Medical Association of Allergologists (AeDA), German Society for Allergology and Clinical Immunology (DGAKI) and Society for Pediatric Allergology and Environmental Medicine (GPA):

Allergic reactions and anaphylaxis to LNP-based COVID-19 vaccines:

Reported orofacial adverse effects from COVID-19 vaccines: the known and the unknown:

Cutaneous adverse effects of available COVID-19 vaccines:

Cumulative adverse event report of anaphylaxis following injections of COVID-19 mRNA vaccine (Pfizer-BioNTech) in Japan: the first month report:

COVID-19 vaccines increase the risk of anaphylaxis:

Biphasic anaphylaxis after exposure to the first dose of the Pfizer-BioNTech COVID-19 mRNA vaccine COVID-19:

Allergenic components of the mRNA-1273 vaccine for COVID-19: possible involvement of polyethylene glycol and IgG-mediated complement activation:

Polyethylene glycol (PEG) is a cause of anaphylaxis to Pfizer / BioNTech mRNA COVID-19 vaccine:

Acute allergic reactions to COVID-19 mRNA vaccines: